According to the latest indictment, a business network led by Z Holding's executives has been accused of manufacturing and distributing... Read more
Category: Uncategorized
TERMS OF SERVICE FOR HEALTHCARE INSIGHT SOCIAL NETWORK
This Terms of Service Agreement ("Agreement", "Terms") for the Healthcare Insight Social Network ("Healthcare Insight") governs the relationship between the platform and... Read more
Harbour inks $90 million antibody deal with bristol myers squibb
Harbour BioMed has officially entered into a strategic partnership with Bristol Myers Squibb (BMS) to jointly develop advanced therapeutic antibodies.... Read more
Fda approves next-generation biologic for severe asthma treatment
The U.S. Food and Drug Administration (FDA) has officially approved Exdensur (depemokimab), an add-on biologic maintenance treatment for severe asthma... Read more
Galux and boehringer ingelheim to jointly explore ai in precision protein design
Galux, a South Korean biotech firm pioneering AI-driven protein therapeutics discovery, has formally entered into a research agreement with Boehringer... Read more
Gilead sciences appoints new head of global legal and compliance
Gilead Sciences Inc. has officially announced the appointment of Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance.... Read more
Chitose and fujifilm biosciences partner to advance biopharmaceutical manufacturing
Life science leaders Chitose Laboratory Corp. and Fujifilm Biosciences Inc. have officially formed a strategic alliance. This partnership aims to... Read more
J&J receives fda approval for innovative lung cancer therapy
The U.S. Food and Drug Administration (FDA) has officially granted approval for Rybrevant Faspro, a therapy targeting epidermal growth factor... Read more
Nxera seeks new buyer for schizophrenia program following boehringer snub
Nxera Pharma (formerly Sosei Group) is actively seeking buyers or strategic partners for its schizophrenia drug program after Boehringer Ingelheim... Read more








